• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Prazosin for Alcohol Use Disorders

Prazosin for Alcohol Use Disorders

February 1, 2019
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Simpson TL et al, Am J Psych 2018; https://doi.org/10.1176/appi.ajp.2018.17080913

TYPE OF STUDY: Randomized, placebo-controlled trial

Prazosin is often used as a second-line option for a broad array of psychiatric conditions, including anxiety, insomnia, nightmares, and post-traumatic stress dis­order (PTSD). It is a high blood pressure medication that also modulates the stress-response system through noradrenergic effects, blocking alpha-1 receptors in the brain. Since stress is a common trigger for excessive drinking, this study set out to test whether prazosin could improve so­briety in alcohol use disorders.

Eighty subjects with alcohol use disorders were randomized to receive either prazosin or placebo. Subjects with PTSD were excluded in order to isolate the potential benefits of prazo­sin for drinking directly. Prazosin was titrated up to a target dosage of 16 mg/ day, as tolerated. All subjects were ac­tively drinking at the start of the study, and they reported their daily alcohol consumption and cravings for the pre­vious day through a toll-free interactive voice system during the 12-week study. Assessments were double-blind, and the primary outcomes were: (1) number of drinks per week, (2) number of drink­ing days per week, and (3) number of heavy drinking days per week.

Compared to placebo, those re­ceiving prazosin reported fewer drinks (mean decrease of 8.0 vs 1.5 drinks per week; p = 0.03) and fewer number of heavy drinking days (mean decrease of 0.8 vs 0.3 days per week; p = 0.01), though the number of drinking days was no less with prazosin. Drowsiness and edema were the only two side ef­fects associated with prazosin.

TCPR’S Take
Given its relatively benign side effect pro­file and established track record, prazosin can already be considered a reasonable second-line option for alcohol use disor­ders. For patients with any combination of anxiety, insomnia, nightmares, PTSD, or hypertension, prazosin is an even more appealing option.
General Psychiatry
KEYWORDS research-update
Michael Posternak, MD.

Adjuvant Clonidine for Mania

More from this author
www.thecarlatreport.com
Issue Date: February 1, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Dark and Light Therapy, TCPR, February 2019
An Opioid Combo Falls Short in Depression
Prazosin for Alcohol Use Disorders
Does Mania Follow the Sun?
CBT for Insomnia
Light and Darkness in Bipolar Disorder
Trintellix and Cognition: A Closer Look
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.